Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients

• J. Feliu ^[1] ; V. Heredia-Soto ^[1] ; R. Gironés ^[2] ; B.Jiménez Munarriz ^[3] ; J. Saldaña ^[4] ; C. Guillén Ponce ^[5] ; M. J. Molina Garrido ^[6]
  1. [1] Medical Oncology Department, H. Universitario La Paz, Madrid
  2. [2] Medical Oncology Department, H. Lluís Alcanyís. Xàtiva
  3. [3] Medical Oncology Department, H. Universitario Clara
  4. [4] Medical Oncology Department, Instituto Catalán de
  5. [5] Medical Oncology Department, H. Universitario Ramón Y
  6. [6] Medical Oncology Department, H. Virgen de La Luz,

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 4, 2020, págs. 457-467
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, so cancer treatment in the older patient remains a therapeutic challenge. The physiological changes associated with aging increase the risk of developing a serious toxicity induced by chemotherapy treatment, as well as other undesirable consequences as hospitalizations, dependence and non-compliance with treatment, that can negatively affect survival, quality of life and treatment efficacy. The use of hematopoietic growth factors and other active supportive interventions in the elderly can help prevent and/or alleviate these toxicities. However, we have little data on the efficacy and tolerance of support treatments in the older patient. The objective of this work is to review the most frequent toxicities of oncological treatments in the elderly and their management.